Feng Na, Simanski Scott, Islam Kazi, Hynan Linda S, Kodadek Thomas, German Dwight C
1Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX USA.
2Department of Chemistry, The Scripps Research Institute, Jupiter, FL USA.
NPJ Parkinsons Dis. 2018 Sep 5;4:28. doi: 10.1038/s41531-018-0064-2. eCollection 2018.
Parkinson disease (PD) is a progressive neurodegenerative disease with motor symptoms that result from degeneration of midbrain dopaminergic neurons. Biomarker research seeks to identify the disease during the pre-symptomatic phase, which is a time when therapeutic intervention will be most helpful. Previously, we screened a combinatorial peptoid library to search for antibodies that are present at much higher levels in the serum of PD patients than in control subjects. One such compound, called the PD2 peptoid, was 84% accurate for the identification of de novo PD when employed as the capture agent in an enzyme-linked immunosorbent assay. This peptoid recognized an IgG3 antibody, and IgG3 levels were also found to be significantly higher in PD vs. control serum. In that study we used samples from the NINDS Parkinson's Disease Biomarker Program. The current study sought to validate that finding using serum samples from de novo and control subjects in the Parkinson's Progression Markers Initiative study. We found no difference in levels of antibodies captured by the PD2 peptoid in the de novo PD vs. control subjects, and no difference in IgG3 serum levels in the two groups. The failure to replicate our previous study appears to be due to the lack of difference in serum IgG3 levels between the PD and control subjects in the current study.
帕金森病（PD）是一种进行性神经退行性疾病，其运动症状由中脑多巴胺能神经元变性引起。生物标志物研究旨在在症状前期识别该疾病，这是治疗干预最有帮助的时期。此前，我们筛选了一个组合类肽文库，以寻找在PD患者血清中水平远高于对照受试者的抗体。一种名为PD2类肽的化合物，在酶联免疫吸附测定中用作捕获剂时，对新发PD的识别准确率为84%。这种类肽识别一种IgG3抗体，并且在PD患者与对照血清中也发现IgG3水平显著更高。在该研究中，我们使用了美国国立神经疾病和中风研究所帕金森病生物标志物项目的样本。当前研究试图在帕金森病进展标志物倡议研究中，使用新发患者和对照受试者的血清样本验证这一发现。我们发现，新发PD患者与对照受试者中被PD2类肽捕获的抗体水平没有差异，两组的IgG3血清水平也没有差异。未能重复我们之前的研究似乎是由于在当前研究中PD患者与对照受试者之间血清IgG3水平没有差异。
